ZA200705516B - Topical stabilized prostaglandin E compound dosage forms - Google Patents

Topical stabilized prostaglandin E compound dosage forms

Info

Publication number
ZA200705516B
ZA200705516B ZA200705516A ZA200705516A ZA200705516B ZA 200705516 B ZA200705516 B ZA 200705516B ZA 200705516 A ZA200705516 A ZA 200705516A ZA 200705516 A ZA200705516 A ZA 200705516A ZA 200705516 B ZA200705516 B ZA 200705516B
Authority
ZA
South Africa
Prior art keywords
dosage forms
compound dosage
topical
stabilized prostaglandin
prostaglandin
Prior art date
Application number
ZA200705516A
Other languages
English (en)
Inventor
Mo Y Joseph
Daniel W Frank
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of ZA200705516B publication Critical patent/ZA200705516B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200705516A 2005-01-06 2007-07-05 Topical stabilized prostaglandin E compound dosage forms ZA200705516B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/030,506 US20050181030A1 (en) 2003-01-03 2005-01-06 Topical stabilized prostaglandin E compound dosage forms

Publications (1)

Publication Number Publication Date
ZA200705516B true ZA200705516B (en) 2008-09-25

Family

ID=36648128

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200705516A ZA200705516B (en) 2005-01-06 2007-07-05 Topical stabilized prostaglandin E compound dosage forms

Country Status (11)

Country Link
US (1) US20050181030A1 (enExample)
EP (1) EP1855648A4 (enExample)
JP (2) JP2008526854A (enExample)
KR (2) KR20070094836A (enExample)
CN (1) CN101132763A (enExample)
AU (1) AU2006204069A1 (enExample)
CA (1) CA2592978C (enExample)
IL (1) IL184322A0 (enExample)
MX (1) MX2007008325A (enExample)
WO (1) WO2006074204A2 (enExample)
ZA (1) ZA200705516B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050009918A1 (en) 2003-04-02 2005-01-13 Nexmed (Holdings) Inc. Prostaglandin compositions and methods for the treatment of vasospasm
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20130211353A1 (en) * 2010-10-28 2013-08-15 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption type formulation
SG190199A1 (en) * 2010-12-02 2013-06-28 Nexmed Holdings Inc Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
EP2693877A4 (en) 2011-04-07 2014-11-19 Nexmed Holdings Inc METHOD AND COMPOSITION FOR TREATING RAYNAUD SYNDROME
ITMI20121462A1 (it) * 2012-08-31 2014-03-01 Francesco Maria Bulletti Preparato a rilascio vaginale per la diagnosi della pervietà e della funzione utero tubarica femminile umana finalizzata alla fecondazione dei gameti

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US623241A (en) * 1899-04-18 Machine for trimming oil-cakes
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
SE431821B (sv) * 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
IE59361B1 (en) * 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US6593369B2 (en) * 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
WO1999066870A1 (en) * 1998-06-25 1999-12-29 Lavipharm Laboratories, Inc. A device and method for the treatment of erectile dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
JP2006512291A (ja) * 2002-09-06 2006-04-13 ネックスメド ホールディングス インコーポレイテッド 男性勃起障害の治療方法
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms

Also Published As

Publication number Publication date
CA2592978C (en) 2013-12-31
KR20070094836A (ko) 2007-09-21
CA2592978A1 (en) 2006-07-13
KR20140006083A (ko) 2014-01-15
CN101132763A (zh) 2008-02-27
MX2007008325A (es) 2007-11-23
IL184322A0 (en) 2007-10-31
EP1855648A2 (en) 2007-11-21
JP2008526854A (ja) 2008-07-24
AU2006204069A1 (en) 2006-07-13
EP1855648A4 (en) 2012-12-19
JP2014055144A (ja) 2014-03-27
WO2006074204A3 (en) 2007-02-08
WO2006074204A2 (en) 2006-07-13
US20050181030A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
IL184322A0 (en) Topical stabilized prostaglandin e compound dosage forms
GB0500492D0 (en) Compound
GB0513702D0 (en) Compound
IL206109A (en) Cinnamide compound
GB0506133D0 (en) Compound
TWI369950B (en) Active compound combinations
ZA200803150B (en) Topical Formulations
IL187279A0 (en) Hydantoin compounds
TWI370130B (en) Two cyclic cinnamide compound
GB0520955D0 (en) Compound
ZA200800368B (en) New pharmaceutical compounds
DK1776090T3 (da) Stabiliseret prostaglandinsammensætning
ZA200902467B (en) Stabilized prostaglandin E composition
PL1888024T3 (pl) Preparat miejscowy
ZA200805137B (en) Fungicidal active compound combination
GB0512429D0 (en) Novel compound
GB0525323D0 (en) Compound
GB0509829D0 (en) Compound
ZA200609845B (en) Cinnamide compound
GB0616173D0 (en) Compound
GB0524685D0 (en) Compound
GB0516378D0 (en) Compound
GB0516558D0 (en) Topical compositions
GB0517519D0 (en) Topical prostaglandin formulation
GB0516314D0 (en) Compound